Phaseline

Companies › Supergene

Supergene: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 3; Neurology, Cardiovascular; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Non-immunogenic recombinant staphylokinase (Fortelyzin®)
Staphylokinase, a plasminogen activator
PLG, PLMNPhase 3Acute Limb Ischemia; Pulmonary Embolism; Ischemic Stroke, AcuteJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05372718Non-immunogenic recombinant staphylokinase (Fortelyzin®)Phase 3Acute Limb IschemiaCardiovascularSep 2026
NCT06362746Non-immunogenic recombinant staphylokinase (Fortelyzin®)Phase 3Pulmonary EmbolismCardiovascularJun 2028
NCT07324837Non-immunogenic recombinant staphylokinase (Fortelyzin®)Phase 3Ischemic Stroke, AcuteNeurologyNov 2028

Targets

PLG (1) PLMN (1)

Companies with the same targets

Ascension Health Jiangsu Jingze Biopharmaceutical Youssef Yammine

Companies built like this

Sandoz Neurona Therapeutics Merz Pharmaceuticals Lupin Intellia Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.